Managing BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Clinical and Operational Perspectives : Episode 11
Opinion
Video
Advancements in BCG-Unresponsive NMIBC and the Impact of Trial Results and Long-Term Follow-Up
Author(s):
Max Kates, MD, discusses how early complete response rates exceeding 50% at 3 months with newer therapies are encouraging, though long-term follow-up remains critical for evaluating durability of response and establishing real-world effectiveness compared with clinical trial outcomes.
Video Player is loading.
- Data for newer therapies have shown that more than 50% of patients with BCG-unresponsive NMIBC experience a complete response after just 3 months of treatment. What are your thoughts on these findings?
- How do these clinical trial outcomes compare to what you see in your clinical practice when treating patients with newer therapies?
- Discuss the importance of long-term follow-up for patients receiving these newer treatments.
- What is your experience in terms of durability of response?
Related Videos
Future Directions of BCG-Unresponsive NMIBC Management
Adoption of New Treatments for BCG-Unresponsive NMIBC
Navigating Treatment Choices and Financial Considerations in BCG-Unresponsive NMIBC
BCG-Unresponsive NMIBC: Balancing Care and Financial Considerations
The Impact of Gene Therapy and Advancements in BCG-Unresponsive NMIBC Treatment
Navigating BCG-Unresponsive NMIBC and Emerging Therapies
Enhancing Access to BCG-Unresponsive NMIBC Treatments
Reducing Resource Expenditure in Clinics with New Gene Therapies for BCG-Unresponsive NMIBC
Cost-Effectiveness and Patient Support in Treating BCG-Unresponsive NMIBC
Discussing Treatment Options for BCG-Unresponsive NMIBC
Related Content
